信：两名接受双重靶向治疗的 IBD 患者感染 SARS-CoV-2。
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.
机构信息
Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
CEMAD - IBD UNIT - Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
出版信息
Aliment Pharmacol Ther. 2021 Mar;53(6):764-765. doi: 10.1111/apt.16271.
Abstract
This article is linked to Al‐Ani et al papers. To view these articles, visit https://doi.org/10.1111/apt.15779 and https://doi.org/10.1111/apt.16297
摘要
本文与 Al-Ani 等人的论文相关。要查看这些文章，请访问 https://doi.org/10.1111/apt.15779 和 https://doi.org/10.1111/apt.16297。
相似文献
1
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.信：两名接受双重靶向治疗的 IBD 患者感染 SARS-CoV-2。
Aliment Pharmacol Ther. 2021 Mar;53(6):764-765. doi: 10.1111/apt.16271.
2
Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.信：接受双重靶向治疗的两位炎症性肠病患者的 SARS-CoV-2 感染情况-作者答复。
Aliment Pharmacol Ther. 2021 Mar;53(6):766-767. doi: 10.1111/apt.16287.
3
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.信件：炎症性肠病药物与严重 COVID-19 结局相关的风险-来自英国 PREPARE-IBD 多中心队列研究的令人安心的见解。
Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.
4
Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?信函：在SARS-CoV-2社区传播活跃时，新冠病毒病（COVID-19）模拟炎症性肠病（IBD）发作的频率有多高？
Aliment Pharmacol Ther. 2021 Mar;53(5):674-675. doi: 10.1111/apt.16240.
5
COVID-19 and IBD drugs: should we change anything at the moment?新冠病毒肺炎与炎症性肠病药物：我们目前是否应做出任何改变？
Gut. 2021 Apr;70(4):632-634. doi: 10.1136/gutjnl-2020-323247. Epub 2020 Nov 19.
6
Reply to the Letter to the Editor: The Incidence and Outcomes of COVID-19 in Patients With IBD: A Rapid Review and Meta-Analysis.致编辑的信的回复：炎症性肠病患者中新冠病毒病的发病率和结局：快速综述与荟萃分析
Inflamm Bowel Dis. 2020 Sep 18;26(10):e127. doi: 10.1093/ibd/izaa172.
7
Anti-SARS-CoV-2 Antibody Responses in Patients With IBD Treated With Biologics: Are We Finding CLARITY?接受生物制剂治疗的炎症性肠病患者的抗严重急性呼吸综合征冠状病毒2抗体反应：我们能找到答案吗？
Gastroenterology. 2021 Dec;161(6):2057-2059. doi: 10.1053/j.gastro.2021.09.019. Epub 2021 Sep 14.
8
[Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease].[新型冠状病毒2019感染对炎症性肠病症状及治疗的影响]
Z Gastroenterol. 2021 Nov;59(11):1189-1196. doi: 10.1055/a-1508-6734. Epub 2021 Jul 16.
9
Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre.对评论的回复：炎症性肠病患者生物治疗前新冠病毒感染的筛查：首要原则是不伤害。 （注：“primum non nŏcēre”是拉丁语，意为“首要原则是不伤害” ）
Dig Liver Dis. 2020 Nov;52(11):1248-1249. doi: 10.1016/j.dld.2020.07.021. Epub 2020 Jul 27.
10
Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?在炎症性肠病（IBD）患者开始生物治疗前，我们是否应该对其进行新型冠状病毒2（SARS-CoV-2）筛查？
Inflamm Bowel Dis. 2021 Jan 19;27(2):291-294. doi: 10.1093/ibd/izaa173.
引用本文的文献
1
Inflammatory Bowel Disease Management during the COVID-19 Pandemic: A Literature Review.新冠疫情期间炎症性肠病的管理：文献综述
Middle East J Dig Dis. 2022 Apr;14(2):155-166. doi: 10.34172/mejdd.2022.269. Epub 2022 Apr 30.
2
Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.信：接受双重靶向治疗的两位炎症性肠病患者的 SARS-CoV-2 感染情况-作者答复。
Aliment Pharmacol Ther. 2021 Mar;53(6):766-767. doi: 10.1111/apt.16287.
本文引用的文献
1
Effect of IBD medications on COVID-19 outcomes: results from an international registry.IBD 药物对 COVID-19 结局的影响：来自国际注册研究的结果。
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.
2
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease.双重靶向治疗：难治性炎症性肠病管理的一种可能选择。
J Crohns Colitis. 2020 Jul 17. doi: 10.1093/ecco-jcc/jjaa149.
3
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.皮质类固醇，而不是 TNF 拮抗剂，与炎症性肠病患者 COVID-19 不良结局相关：来自国际登记处的结果。
Gastroenterology. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.
4
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.意大利 IBD 患者中 79 例 COVID-19 的结局：一项 IG-IBD 研究。
Gut. 2020 Jul;69(7):1213-1217. doi: 10.1136/gutjnl-2020-321411. Epub 2020 Apr 30.
5
Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.综述文章：炎症性肠病患者 COVID-19 的预防、诊断和管理。
Aliment Pharmacol Ther. 2020 Jul;52(1):54-72. doi: 10.1111/apt.15779. Epub 2020 May 26.
6
Early Risk Factors for the Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Positivity in Patients With Coronavirus Disease 2019.COVID-19 患者严重急性呼吸综合征冠状病毒 2 病毒阳性持续时间的早期危险因素。
Clin Infect Dis. 2020 Nov 19;71(16):2061-2065. doi: 10.1093/cid/ciaa490.
7
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.新加坡 2019 年新型冠状病毒肺炎患者的流行病学特征和临床病程
JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.
Zotero 插件